Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 412

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 412
---
           |     |   202217033481 |     | 12/01/2041 |     | under examination |
| JP      |     | PCT  |     | 12/01/2021  |     |        2022542046 |     |            |     |           |     |     2023510770 |     | 12/01/2041 |     | under examination |
| KR      |     | PCT  |     | 12/01/2021  |     |     1020227027291 |     |            |     |           |     |  1020220128638 |     | 12/01/2041 |     | under examination |
| US      |     | PCT  |     | 12/01/2021  |     |          17791282 |     |            |     |           |     |    20230121528 |     | 12/01/2041 |     | under examination |

251 Darnatein Corporate Overview Darnatein is developing design -augmented(DA) biologics for age -relatedand other degenerative diseases, such as osteoarthritis and spine and joint disorders. Darnatein’s lead DA biologics are intended to be injected directly into pathological tissues to promote regeneration of target tissues such as bone or cartilage cells. Leveraging these innovative DA biologics to regenerate bone and cartilage has the potential to restore functionality and reduce pain across several degenerative conditions. Darnatein has identified and advanced two therapeutic candidates, DRT -102, a clinical -stageasset for spinal fusion, and DRT -101, a pre -clinicalstage asset for osteoarthritis. A small exploratory, clinical trial of 15 patients with DRT -102indicated potential efficacy compared to a placebo, with no serious adverse events reported. Safety and efficacy evaluation will be determined following review of all safety data by relevant regulatory agencies. Larger clinical trials will be required to provide more extensive and accurate data on the safety and effectiveness of DRT102. A pre -clinical(non -human) trial of DRT -101demonstrated cartilage regeneration and joint healing in animals, with no serious adverse events reported. Based on these preliminary results, Darnatein intends to continue the development and testing of DRT -101and, when additional resources are available, DRT -102. Darnatein has not